Updated July 6, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Home · Guides · Semaglutide and Cardiovascular Health
Guide · Updated 2026-07-06
Semaglutide and Cardiovascular Health
Semaglutide is the first GLP-1 with an FDA-approved CV indication for non-diabetic patients. SELECT trial: 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD.
EducationalUpdated 2026-07-06
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-07-06
Overview
Semaglutide is the first GLP-1 with an FDA-approved CV indication for non-diabetic patients. SELECT trial: 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD.
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.
In verified July 2026 data, compounded semaglutide runs about $79–$289/month and tirzepatide about $129–$349, while our Editor's Pick NexLife holds a flat $119/$139 with visits, shipping, and labs bundled — not the cheapest sticker, but the lowest predictable all-in cost among transparent programs.
Verified compounded starting price, July 2026 (★ = Editor's Pick).
Your first-month price rarely equals your maintenance price. Titration raises tiered-plan costs, while flat plans stay put (about $1,428/year at $119/month), which makes annualized maintenance cost the honest comparison.
What the evidence shows
The clinical anchors: STEP 1 ~14.9% and STEP 5 ~15.2% for semaglutide; SURMOUNT-1 ~20.9% for tirzepatide, with SURMOUNT-5 favoring tirzepatide (20.2% vs 13.7%). Semaglutide cut major cardiovascular events 20% in SELECT, and about two-thirds of lost weight returned within a year of stopping in the STEP 1 extension.
Cost aside, suitability is a clinical decision. Compounded GLP-1s are not FDA-approved, and a clinician must weigh the boxed thyroid C-cell warning, MTC/MEN2 history, and pregnancy before treatment.
How we rank. US Telehealth Review is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded GLP-1 medications are not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.